SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

  • End date
    Sep 1, 2023
  • participants needed
  • sponsor
    Sichuan Baili Pharmaceutical Co., Ltd.
Updated on 23 April 2022


This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.

Condition Esophageal Squamous Cell Carcinomas
Treatment Irinotecan, SI-B001
Clinical Study IdentifierNCT05022654
SponsorSichuan Baili Pharmaceutical Co., Ltd.
Last Modified on23 April 2022


Yes No Not Sure

Inclusion Criteria

Male or female, age: ≥18 years and ≤75 years
Expected survival time ≥3 months
Locally advanced esophageal squamous cell carcinoma confirmed histologically or pathologically as recurrent or metastatic or without indications of radical local treatment
Patients who had failed or were intolerant to prior anti-PD-1 (L1) mab or anti-PD-1 (L1) mab combined with chemotherapy
Previously only received ≤2 line therapy for recurrent and metastatic esophageal squamous cell carcinoma
Agree to provide archived tumor tissue specimens of primary or metastatic lesion (4 surgical specimens (thickness 5μm) without staining section (anti-removal);6 unstained sections (anti-removal) surgical specimens (thickness 10μm) or fresh tissue samples, if the patient cannot provide, can be included after the investigator's judgment
There must be at least one measurable lesion conforming to the RECIST V1.1 definition. Tumor lesion located in the area of previous radiotherapy or other local and regional treatment sites is generally not a measurable lesion unless there is definite progression of the lesion or the lesion persists three months after radiotherapy
Physical fitness ECOG score of 0 or 1
Toxicity from previous antitumor therapy has returned to ≤1 as defined by NCI-CTCAE V5.0 (except for toxicity that the investigators determined to be of no safety risk, such as hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism after hormone replacement therapy)
Organ function levels must meet the following requirements and meet the following
Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥90×10^9/L, hemoglobin ≥90 g/L; B) Liver function: Total bilirubin TBIL≤1.5×ULN (total bilirubin ≤3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver metastasis), AST and ALT ≤2.5×ULN in patients without liver metastasis, AST and ALT ≤5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to Cockcroft and Gault formula); D) Urine routine / 24-hour protein quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24 hours < 1g can be included); E) Cardiac function: left ventricular ejection fraction ≥50%; F) Coagulation function: International standardized ratio (INR) ≤1.5×ULN, and activated partial thrombin time (APTT) ≤1.5×ULN
Eligible patients (male and female) who are fertile must agree to use a reliable
contraceptive method (hormonal or barrier method or abstinence, etc.) with
their partner during the trial and for at least 6 months after the last
medication;Women of childbearing age must have a negative blood or urine
pregnancy test within 7 days prior to the first use of the study drug

Exclusion Criteria

Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug, except for the following
Oral fluorouracil and small molecule targeted drugs were used within 2 weeks
before the first administration of the study drug or within 5 half-lives of
the drug; The traditional Chinese medicines with anti-tumor indications were
within 2 weeks before the first use of the study drug
Patients with esophageal fistula
Received an unmarketed clinical investigational drug or treatment within 4 weeks prior to initial use of the investigational drug
Had major organ surgery (excluding needle biopsy, tracheotomy, gastrostomy, etc.) or had significant trauma within 4 weeks prior to the first use of study drugs, or needed to undergo elective surgery during the trial
Previous allogeneic hematopoietic stem cell transplantation or organ transplantation
A history of serious cardiovascular and cerebrovascular diseases, including but not limited to
Severe cardiac rhythm or conduction abnormalities, such as ventricular
arrhythmias requiring clinical intervention, grade iii atrioventricular block
etc; In the resting state, QT interval was prolonged (QTc > 450 msec in men or
QTc > 470 msec in women); Acute coronary syndrome, congestive heart failure
aortic dissection, stroke or other grade 3 or higher cardio-cerebrovascular
events within 6 months prior to the first administration; New York Heart
Association (NYHA) heart function grade ≥II heart failure
Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus, inflammatory bowel disease, etc., except type I diabetes, hypothyroidism that can be controlled only with replacement therapy, and skin diseases that do not require systemic treatment
Patients with a history of other malignant tumors and signs of recurrence and metastasis within 1 year before the first administration
Poorly controlled hypertension (systolic blood pressure & GT;150 mmHg or diastolic pressure &gt;100 mmHg)
Pulmonary disease of grade 3 or higher defined by CTCAE V5.0;Patients with past or present interstitial lung disease (ILD)
Cerebral parenchymal or meningeal metastases with clinical symptoms were not suitable for inclusion
Previous use of anti-EGFR antibody drug therapy
There are known allergic contraindications to any excipients of SI-B001 or irinotecan
Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection
Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, septicemia, etc;'
Pregnant or lactating women
Persons with mental disorders or poor compliance
The investigator considers that the subject has a history of other serious systemic diseases or other reasons to be unsuitable for this clinical study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note